Antisense therapy for cancer - The time of truth

Lancet Oncology

Volumn 3, Issue 11, 2002, Pages 672-683

  Jansen, Burkhard ^a,b   Zangemeister Wittke, Uwe ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFFINITAC; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; BUSULFAN; CARBOPLATIN; CGP 69846A; CLUSTERIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; GENE EXPRESSION MODULATOR 231; GTI 2040; ISIS 2503; ISIS 3521; LR 3001; MESSENGER RNA; MG 98; NUCLEASE; NUCLEOSIDE; OBLIMERSEN; OGX 011; OGX 133; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PACLITAXEL; PROTEIN C MYB; PROTEIN KINASE C; PROTEIN P53; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; BINDING AFFINITY; CANCER; CANCER CELL; CELL GROWTH; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA HYBRIDIZATION; DRUG MECHANISM; DRUG SPECIFICITY; DRUG TARGETING; FATIGUE; GENE CONTROL; GENE FUNCTION; GENE SEQUENCE; GENOMICS; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEOMICS; REVIEW; RNA BINDING; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 0036846993     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00903-8     Document Type: Review

References (75)

1. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-98.
2. Belikova AM, Zarytova VF, Grineva NI. Synthesis of ribonucleosides and diribonucleosides phosphates containing 2-chloroethylamine and nitrogen mustard residues. Tetrahedron Lett 1967;37:3557-62.
3. Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 1977; 74: 4370-74.
4. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978; 75: 280-84.
5. Donis-Keller H. Site specific enzymatic cleavage of RNA. Nucleic Acids Res 1979; 7: 179-92.
6. Monia BP, Lesnik EA, Gonzalez C, et al. Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993; 268: 14514-22.
7. Bacon TA,Wickstrom E. Walking along human c-MYC mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5' cap region. Oncogene Res 199 1; 6: 13-19.
8. Monia BP, Johnston IF, Geiger T, et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996; 2: 668-75.
9. Ziegler A, Luedke GH, Fabbro D, et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Nat Cancer Inst 1997; 89: 1027-36.
10. Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol 1997;15:537-41.
11. Ho SP, Bao Y, Lesher T, et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol 1998;16:59-63.
12. Mathews DH, Sabina J, Zuker M, Turner DH. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 1999; 288: 911-40.
13. Tu GC, Cao QN, Zhou F, Israel Y. Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design. J Biol Chem 1998; 273: 25125-31.
14. Crooke ST. Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev 1998; 8: 133-34.
15. Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta 1999;1489:53-68.
16. Krieg AM, Yi AK, Hartmann G. Mechanisms and therapeutic applications of immune stimulatory cpG DNA. Pharmacol Ther 1999;84:113-20.
17. Hoke GD, Draper K, Freier SM, et al. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acid Res 1991;19:5743-48.
18. Martin P. A new access to 2'-O-alkylated ribonucleosides and properties of 2'-O-alkylated oligoribonucleotides. Helvetica Chimica Acta 1995; 78: 486-504.
19. Kandimalla ER, Manning A, Zhao Q, et al. Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'- 5-'deoxyribonucleotide segments. Nucleic Acid Res 1997; 25: 370-78.
20. Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids Proc Natl Acad Sci USA 2000; 97: 5633-38.
21. Wang H, Cai Q, Zeng X, et al. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proq Natl Acad Sci USA 1999; 96: 13989-94.
22. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
23. Adams JM, Cory S. The BCL-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-26.
24. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
25. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7: 14-23.
26. Stein CA. Is irrelevant clevage the price of antisense efficacy? Pharmacol Ther 2000; 85: 231-36.
27. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-41.
28. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of BCL-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-23.
29. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. BCL-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med 1998; 4: 232-34.
30. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both BCL-2 and BCL-XL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000;6:2547-55.
31. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL-2 antisense therapy. Lancet 2000; 356: 1728-33.
32. Boise LH, González-Garcia M, Postema CE, et al. BCL-X, a BCL-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
33. Leech SH, Olie RA, Gautschi O, et al. Induction of apoptosis in lung-cancer cells following BCL-XL antisense treatment. Int I Cancer 2000; 86: 570-76.
34. Simoes-Wust AP, Olie RA, Gautschi O, et al. BCL-XL antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer 2000;87:582-90.
35. Lebedeva I, Rando R, Ojwang J, et al. BCL-XL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000; 60: 6052-60.
36. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous BCL-XS through the control of BCL-X pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 1999; 17: 1097-100.
37. Gautschi O, Tschopp S, Olie RA, et al. Activity of a novel BCL2/BCL-XL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001; 93: 463-71.
38. Yuspa SH, Dlugosz AA, Cheng CK, et al. Role of oncogenes and tumor suppressor genes in multistage carcinogenesis. J Invest Dermatol 1994; 103: 90S-5S
39. Yazaki T, Ahmad S, Chahlavi A, et al. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol 1996;50:236-42.
40. Geiger T, Muller M, Dean NM, Fabbro D. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 1998; 13: 35-45.
41. Cotter FE. Antisense oligonucleotides for haematological malignancies. Haematologica 1999; 84:19-22.
42. Alavi JB, Grossman SA, Supko J, et al. Efficacy, toxicity, and pharmacology of an antisense oligonuclecitide directed against protein kinase C-alpha (ISIS 3521) delivered as a 21 day continous intravenous infusion in patients with recurrent high grade astrocytomas (HGA). Proc Am Soc Clin Oncol 2000; 19: 167.
43. Yuen A, Advani R, Fisher G, et al. A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Am Soc Clin Oncol 2000; 19: 459a.
44. Yuen A, Halsey J, Lum B, et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC, with carboplatin and paclitaxel in nonsmall cell lung cancer. Clin Cancer Res 2000; 6 (suppl): 4572s.
45. Tamm I, Dorken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001; 358: 489-97.
46. Howe LR, Leevers SJ, Gomez N, et al. Activation of the MAP kinase pathway by the protein kinase raf. Cell 1992; 71: 335-42.
47. Kasid U, Pfeifer A, Brennan T, et al. Effect of antisense c-RAF-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 1989; 243: 1354-56.
48. Stevenson JP, Yao KS, Gallagher M, et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-RAF-1 antisense oligonuclecitide ISIS 5132 (CGP 69846A) J Clin Oncol 1999;17:2227-36.
49. Cunningham CC, Holmlund JT, Schiller JH, et al. A phase I trial of c-RAF kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2000; 6: 1626-31.
50. Oza AM, Eisenhauer E, Swenerton K, et al. Phase II study of c-RAF kinase antisense oligonucleotide ISIS 5132 in patients with recurrent ovarian cancer. Clin Canc Res 2000; 6 (suppl): 4572.
51. Bradbury AW, Carter DC, Miller WR, et al. Protein kinase A (PKA) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer 1994; 69: 738-42.
52. Ciardiello F, Caputo R, Bianco R, et al. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J Natl Cancer Inst 1998; 90: 1087-94.
53. Tortora G, Bianco R, Damiano V, et al. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin Cancer Res 2000; 6:2506-12.
54. Bishop MR, Jackson JD, Tarantolo SR, et al. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J Hematother 1997; 6: 441-46.
55. Tortora G, Caputo R, Damiano V, et al. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int J Cancer 2000; 88: 804-09.
56. Biedenkapp H, Borgmeyer U, Sippel AE, Klempnauer KH. Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature 1988; 335: 835-37.
57. Barletta C, Pelicci PG, Kenyon LC, et al. Relationship between the c-MYB locus and the 6q-chromosomal aberration in leukemias and lymphomas. Science 1987; 235: 1064-67.
58. Ratajczak MZ, Hijiya N, Catani L, et al. Acute- and chronic-phase chronic myclogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-MYB antisense oligodeoxynucleotides. Blood 1992; 79: 1956-61.
59. MacLeod AR, Rouleau J, Szyf M. Regulation of DNA methylation by the RAS signaling pathway. J Biol Chem 1995; 270:11327-37.
60. Ramchandani S, MacLeod AR, Pinard M, et al. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1997; 94: 684-89.
61. Siu LL, Gelmon KA, Moore MJ, et al. A phase I and pharmacokinetik (PK) study of the human DNA methyltransferase (Metase) antisense oligodeoxynucleotide MG98 given as a 21-day continous infusion every 4 weeks. Proc Am Soc Clin Oncol 20001; 19: 250.
62. Skorski T, Nieborowska-Skorska M, Nicolaides NC, et al. Suppression of Philadelphia 1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1994; 91: 4504-08.
63. de Fabritiis P, Petti MC, Montefusco E, et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998; 91: 3156-62.
64. Humphreys DT, Carver JA, Easterbrook- Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999; 274: 6875-81.
65. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000; 6: 1655-63.
66. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-583. 1998.
67. Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60: 2805-09.
68. Saleh M, Posey J, Pleasani L, et al. A phase II trial of ISIS 2503, an antisense inhibitor of h-RAS, as first line therapy for advanced colorectal carcinoma. Proc Am Soc Clin Oncol 2000; 19: 320.
69. Bos JL. RAS oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-89.
70. Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000; 60: 3058-64.
71. Nickerson T, Miyake H, Gleave ME, Pollak M. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res 1999; 59: 3392-95.
72. Kinoshita H, Yoshikawa H, Shiiki K, et al. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95- mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 2000; 88: 986-91.
73. Nylandsted J, Rohde M, Brand K, et al. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses BCL-2. Proc Natl Acad Sci USA 2000; 97: 7871-76.
74. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
75. McGill GG, Horstmann M, Widlund HR, et al. BCL-2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002; 109: 707-18.